Additional information for IV administration
• Infusion-site reactions: erythema, pruritus, pain, induration and
thrombophlebitis
• Lower risk of systemic hypersensitivity reactions and infusion-site adverse
reactions compared to IV fosaprepitant 41
• Not interchangeable with fosaprepitant IV 7
• Infusion site reactions: majority including thrombophlebitis and vasculitis,
reported with concomitant vesicant chemotherapy administration, particularly
when associated with extravasation
• Should always be diluted and given as a slow intravenous infusion
• Not interchangeable with aprepitant IV 7
• No infusion site or anaphylactic reaction related to IV NEPA 72
• Safety profile generally similar to that seen with oral NEPA
• IV NEPA may be better tolerated than other NK 1 RAs (clinical trial
information: NCT03403712)
• Quick onset of infusion-related hypersensitivity reactions (most reactions
occur within first few minutes of administration)
• Patients should be consulted to determine if they are hypersensitive to any
component of the product, including soybean oil
• In case of known allergies to legumes, soybean oil or other related allergens
(including peanuts), monitor patients closely
events (within 1 hour of infusion)
compared with fosaprepitant. 7,36,41
An overview of intravenously
administered NK 1 RA formulations
is presented in Table 1.
Netupitant
Oral formulation
NEPA is an oral fixed combination
of the highly selective NK 1
RA netupitant 300mg and the
pharmacologically and clinically
distinct 5-HT 3 RA, palonosteron
0.5mg. Netupitant is not available
as a single agent. Similar to
aprepitant, it inhibits CYP3A4,
so the possibility of drug–drug
interactions must be taken
hospitalpharmacyeurope.com | 2019 | 59